Updated:
Prange Beteiligungen
Prange Beteiligungen AG succeeded the 1984-founded MVB Beteiligungsgesellschaft and now consolidates the Prange family's direct holdings. Otto Prange, a...
Prange Beteiligungen
Prange Beteiligungen AG succeeded the 1984-founded MVB Beteiligungsgesellschaft and now consolidates the Prange family's direct holdings. Otto Prange, a certified auditor, established the platform; his son Axel participates in operations alongside managing directors Dietmar Rohleder and Sebastian Heckerodt. The firm executes majority buyouts and growth investments in private equity, real estate, and distressed situations. It also maintains minority positions through SPVs and co-investments. Confirmed holdings include stakes in Adragos Pharma alongside FSN Capital and Aprilia Animal Health with Angelo Gatto. Geographic reach centers on Europe with production facilities in Germany, France, Italy, Norway, and Japan. Additional exposure reaches eight countries through portfolio operations. More than 1,500 employees work inside the majority-owned companies. Separate minority investments cover entities employing over 6,000 people globally. The group maintains no disclosed additional offices beyond its Plettenberg headquarters. Philanthropic activity occurs through prange akzente e.V., established in 2005 to support education, social projects, animal welfare, and sports. Control remains inside the founding family with no external limited partners or succession vehicles disclosed. This structure allows direct operational involvement in portfolio companies and avoids the reporting layers typical of multi-family offices or fund-of-funds vehicles.
General information
Firm type
Single Family Office
Year founded
1984
Location
Region
Europe
Country
Germany
City
Plettenberg
Corporate office
Plettenberg, Germany
Principals
Otto Prange
Founder and Chairman of Prange Group
Axel Prange
Family Member
Dietmar Rohleder
Managing Director at Prange Beteiligungen AG
Sebastian Heckerodt
Managing Director of Prange Pharma GmbH
Sector focus
Frequently asked questions
Who runs investment decisions at Prange Beteiligungen?
Otto Prange serves as founder and chairman. Dietmar Rohleder acts as managing director of the holding company while Sebastian Heckerodt oversees the pharma subsidiary.
Does Prange Beteiligungen participate in fund commitments or only direct deals?
The firm executes direct majority buyouts, co-investments, and SPVs. It does not disclose allocations to external funds.
What investment stages does Prange Beteiligungen typically target?
Activity centers on buyouts and growth equity. Selected venture capital and distressed positions also appear in the portfolio.
Where does the underlying wealth come from?
The capital originates from the Prange family, which built its position through industrial and professional services holdings.
How is Prange Beteiligungen related to its portfolio companies?
The office holds controlling interests in more than sixty companies and maintains active oversight rather than passive minority stakes.
Does Prange Beteiligungen maintain philanthropic structures?
Yes. The family channels giving through prange akzente e.V., founded in 2005, which supports education, social projects, nature conservation, and sports.
Which sectors does Prange Beteiligungen explicitly prioritize?
Core areas include healthcare services, industrial technology, climate technology, proptech, agritech, and data analytics.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: